G. Coteur

2.5k citations

54 papers · 2.0k indexed · h-index 23

Impact in

Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
Hematology top 2%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 27
- Rheumatoid Arthritis Research and Therapies 20
- Spondyloarthritis Studies and Treatments 15
Immunology 19
- Psoriasis: Treatment and Pathogenesis 11

Co-authors: Dorothy L. Keininger Philip J. Mease Philippe Dúbois Brian G. Feagan Michel Warnau Roy Fleischmann Ronald van Vollenhoven Joachim Sieper
Journals: Value in Health (11 papers)Annals of the Rheumatic Diseases (10 papers)Alimentary Pharmacology & Therapeutics (3 papers)The American Journal of Gastroenterology (2 papers)Archives of Environmental Contamination and Toxicology (2 papers)
Partner nations: Belgium United States Germany

In The Last Decade

G. Coteur

49 papers receiving 1.9k citations

Peers

Countries citing papers authored by G. Coteur

Since Specialization

Citations

This map shows the geographic impact of G. Coteur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Coteur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Coteur more than expected).

Fields of papers citing papers by G. Coteur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Coteur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Coteur. The network helps show where G. Coteur may publish in the future.

Co-authorship network

The 25 scholars most cited alongside G. Coteur, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G. Coteur Line = papers co-authored together G. Coteur links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PRS78 Burden of Idiopathic Pulmonary Fibrosis (IPF) on Quality of Life (QOL), Work Productivity and Healthcare Use Value in Health ·G. Coteur, Yoshikazu Inoue, Vincent Cottin, Mark Small, James Siddall, Jonathan Langley, Francesco Bonella, Lisa Lancaster	2020	0
2	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity Arthritis Research & Therapy ·Janet Pope, Clifton O. Bingham, Roy Fleischmann, Maxime Dougados, Elena Massarotti, J. Wollenhaupt, Benjamin Duncan, G. Coteur, Michael E. Weinblatt	2015	12
3	Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study Value in Health ·Paul Emery, Kazuhiro Sadasue, Abdulssalam El-Suleiman, V. Bykerk, Daniel E. Furst, Xavier Mariette, O. Purcaru, G. Coteur, Jeremy Lawson, Michael E. Weinblatt	2015	1
4	Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical Trial Value in Health ·John Kirwan, G. Coteur, Emma Dures, J. Nicklin, Judy C. Bryson, Sarah Hewlett	2014	4
5	Re-Validation of the Self-Injection Assessment Questionnaire© (Siaqv2.0©) in Rheumatoid Arthritis Patients on Certolizumab Pegol Treatment Value in Health ·G. Coteur	2014	1
6	Long-Term Maintenance of Improvements in Patient-Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 48-Week Results of the Rapid-axSpA Study Value in Health ·J. Sieper, Андрій Самойлов, Astrid van Tubergen, Atul Deodhar, G. Coteur, Pritibha Singh, R. Landewé	2013	2
7	Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study Value in Health ·Dafna D. Gladman, Roy Fleischmann, G. Coteur, Franz Woltering, Philip J. Mease	2013	3
8	Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 48-Week Patient-Reported Outcome Results of the Rapid-PsA Study Value in Health ·Dafna D. Gladman, R Fleischmann, G. Coteur, Luke Peterson, Delgado Domínguez	2013	2
9	Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study Value in Health ·Joachim Sieper, A. Kivitz, Astrid van Tubergen, Atul Deodhar, G. Coteur, Franz Woltering, Robert Landewé	2013	7
10	Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study Data Archiving and Networked Services (DANS) ·Robert Landewé, Martín Rudwaleit, Désirée van der Heijde, Maxime Dougados, Walter P. Maksymowych, Colin Bayne-Jardine, Godfrey Chifung, C. Stach, Bengt Hoepken, G. Coteur, Danuta Kielar, Andreas Fichtner, T. Arledge, J. Sieper	2012	10
11	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension British Journal of Dermatology ·Kristian Reich, J.‐P. Ortonne, Alice B. Gottlieb, Daniil Rastorguev, G. Coteur, Chantal Tasset, Philip J. Mease	2012	127
12	PGI4 Health-Related Quality of Life Improvements in Patients with Active Crohn's Disease Following Treatment with Certolizumab Pegol in the Music Study (NCT00297648) Value in Health ·Xavier Hébuterne, Marc Lémann, G. Coteur, Étienne Ernault, J F Colombel	2011	0
13	PMS61 Rapid Reductions in Fatigue and Sleep Problems and Correlation with Improvements in Patient-Reported Outcomes in Patients with Active RA Treated with Certolizumab Pegol in the realistic 12-Week Phase IIIB Randomised Controlled Study Value in Health ·Janet Pope, R. Fleischmann, Maxime Dougados, Clifton O. Bingham, Elena Massarotti, J. Wollenhaupt, Benjamin Duncan, G. Coteur, Michael E. Weinblatt	2011	3
14	Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial The Journal of Rheumatology ·Edward Keystone, Jeffrey R. Curtis, Roy Fleischmann, Daniel E. Fürst, Dinesh Khanna, Josef S Smolen, Philip J. Mease, Michael Schiff, G. Coteur, O. Davies, Bernard Combe	2011	37
15	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial Annals of the Rheumatic Diseases ·Vibeke Strand, Josef S Smolen, Ronald van Vollenhoven, Philip J. Mease, Gerd R Burmester, Falk Hiepe, Dinesh Khanna, E. Nikaï, G. Coteur, Michael Schiff	2011	54
16	Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease Alimentary Pharmacology & Therapeutics ·G. Coteur, Brian G. Feagan, Dorothy L. Keininger, Mark Kosinski	2009	111
17	Environmental factors influencing the immune responses of the common European starfish (Asterias rubens) Fish & Shellfish Immunology ·G. Coteur	2003	34
18	Differentiation of immune cells challenged by bacteria in the common European starfish, Asterias rubens (Echinodermata) European Journal of Cell Biology ·G. Coteur, A.K. MALLIK, Michel Warnau, Michel Jangoux, Philippe Dúbois	2002	31
19	Reactive oxygen species (ROS) production by amoebocytes of Asterias rubens (Echinodermata) Fish & Shellfish Immunology ·G. Coteur, Michel Warnau, Michel Jangoux, Philippe Dúbois	2002	79
20	Effects of PCBs on Reactive Oxygen Species (ROS) Production by the Immune Cells of Paracentrotus lividus (Echinodermata) Marine Pollution Bulletin ·G. Coteur, Bruno Danis, S.W. Fowler, JL Teyssié, Philippe Dúbois, Michel Warnau	2001	49

About G. Coteur

G. Coteur is a scholar working on Rheumatology, Immunology, Aquatic Science, Hematology and Health, Toxicology and Mutagenesis, having authored 54 papers that have together received 2.0k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (15 papers), Psoriasis: Treatment and Pathogenesis (11 papers), Inflammatory Bowel Disease (9 papers), Autoimmune and Inflammatory Disorders Research (8 papers), Microscopic Colitis (8 papers), Environmental Toxicology and Ecotoxicology (8 papers) and Marine Bivalve and Aquaculture Studies (7 papers). The work is most often cited by research in Rheumatology (1.0k citations), Hematology (471 citations), Immunology (794 citations), Aquatic Science (149 citations) and Genetics (126 citations). G. Coteur has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Dorothy L. Keininger, Philip J. Mease, Philippe Dúbois, Brian G. Feagan, Michel Warnau, Roy Fleischmann, Ronald van Vollenhoven, Joachim Sieper, Mark Kosinski and Bruno Danis. Their work appears in journals such as Value in Health, Annals of the Rheumatic Diseases, Alimentary Pharmacology & Therapeutics, The American Journal of Gastroenterology and Archives of Environmental Contamination and Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact